4//SEC Filing
Sullivan Timothy Eugene 4
Accession 0001127602-25-021248
CIK 0001492422other
Filed
Sep 9, 8:00 PM ET
Accepted
Sep 10, 4:02 PM ET
Size
10.7 KB
Accession
0001127602-25-021248
Insider Transaction Report
Form 4
Sullivan Timothy Eugene
Chief Financial Officer
Transactions
- Exercise/Conversion
Stock Option (Right to Buy)
2025-09-08−15,000→ 242,903 totalExercise: $10.03Exp: 2027-10-18→ Common Stock (15,000 underlying) - Exercise/Conversion
Common Stock
2025-09-08$10.03/sh+15,000$150,450→ 143,665 total - Sale
Common Stock
2025-09-08$27.86/sh−32,729$911,830→ 110,936 total - Sale
Common Stock
2025-09-08$27.83/sh−10,000$278,300→ 60,396 total(indirect: By Trust)
Footnotes (4)
- [F1]This is a scheduled exercise & sale from 10b5-1 trading plan dated June 9, 2025.
- [F2]The price reported is a weighted average price. These shares were sold in multiple transactions at prices ranging from $27.67 to $27.98, inclusive. The reporting person hereby undertakes to provide, upon request, to the staff of the Securities and Exchange Commission, the issuer or a security holder of the issuer full information regarding the number of shares sold at each separate price.
- [F3]The securities are held by The Timothy E Sullivan Irrevocable Trust of 2023. Patrick O. Collins is the trustee of The Timothy E Sullivan Irrevocable Trust of 2023. The reporting person disclaims beneficial ownership over the shares held by The Timothy E Sullivan Irrevocable Trust of 2023 except to the extent of his pecuniary interest therein.
- [F4]This option was granted on October 18, 2017 and fully vested.
Documents
Issuer
Apellis Pharmaceuticals, Inc.
CIK 0001492422
Entity typeother
Related Parties
1- filerCIK 0001707000
Filing Metadata
- Form type
- 4
- Filed
- Sep 9, 8:00 PM ET
- Accepted
- Sep 10, 4:02 PM ET
- Size
- 10.7 KB